TNFSF10 and prostate cancer: Docetaxel and TRAIL co-treatment induced apoptosis in 28.6% ± 7.35% cells in a concentration of 0.25 μM and 28.6% ± 3.5% in a concentration of 0.5 μM in DU45 prostate cancer cell line.